A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer. READ MORE
IBM’s Watson for Oncology, a computer that helps oncologists make treatment decisions for individual patients, made the same recommendations 90% of the time as a team of specialist oncologists, according to a new study presented on Friday, December 9, at the San Antonio Breast Cancer Symposium.
Research in Review
Use of the 21-gene recurrence score assay (RS) can help to reduce health care spending and improve breast cancer treatment, but the extent of the benefit offered differs between younger women and those aged 75 years and older.
An observational study of more than 100,000 women with a diagnosis of ductal carcinoma in situ (DCIS, or Stage 0 breast cancer) and published in JAMA Oncology, showed that age and ethnicity are important risk factors for death from breast cancer following a DCIS diagnosis, according to findings that estimated the 10- and 20-year mortality in this patient population.